In a 12-patient-per-arm pilot study reported November 5, Eton Pharmaceuticals found that its extended-release zinc acetate formulation ET-700 caused treatment-related adverse events in just 1 of 12 participants, compared with 8 of 12 on GALZIN, the FDA-approved zinc acetate standard that has been in use since 1997. The tolerability gap is striking. The complication is what came with it.
On the efficacy side, ET-700 reduced hepatic copper uptake by only 12% in the prespecified primary analysis, against a 46% reduction with GALZIN and an 11% increase with placebo. The extended-release design that smoothed the GI profile also blunted the drug’s ability to block copper absorption, which is the entire therapeutic purpose in Wilson disease, a rare inherited condition. Eton now has a formulation that patients tolerate far better and that does meaningfully less of what a Wilson disease maintenance therapy needs to do.
The company is not treating this as a dead end. Based on these pilot results, Eton says it is already developing faster-release formulations of ET-700 and plans to test them in additional study arms in 2027, with the goal of recovering copper inhibition while keeping the tolerability advantage. The logic is straightforward: if the release rate is the variable controlling both outcomes, titrating it should produce a formulation somewhere between the two extremes. Whether that middle ground exists at a clinically meaningful copper-inhibition level is what 2027 will have to answer.
This is a small pilot, 12 participants per active arm, so no conclusions about efficacy or safety magnitude should be drawn at scale. What the data do establish clearly is that the extended-release mechanism created a real tolerability difference and a real efficacy cost, giving the formulation team a defined problem to solve rather than an ambiguous signal. The number to watch from the 2027 arms is hepatic copper uptake reduction: if faster-release versions can get that figure into a range comparable to GALZIN while holding GI adverse events below the 8-of-12 rate seen here, ET-700 becomes a genuinely differentiated candidate in a disease where long-term tolerability drives adherence.
Source link: https://www.sec.gov/Archives/edgar/data/1710340/000143774926035258/eton20261104_8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
